Companies /Healthcare

Iovance Biotherapeutics Inc

NASDAQ: IOVA Biotechnology
$7.66
▼ $0.10 (−1.31%) today
Markets open · 3:00pm ET

24/7 Wall St. View

IOVA at a Glance

Valuation
Market cap
$3.6B
Profitability
Revenue (TTM)
$379.0M
Profit margin
-58.2%
EPS (TTM)
$-0.49
Price
52-week range
$2 – $15
Street target
$14.50

Headquartered in Philadelphia, PA Fiscal year ends December NASDAQ: IOVA iovance.com

About Iovance Biotherapeutics

Iovance Biotherapeutics is a commercial-stage biotechnology company that develops, manufactures and delivers polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors.

**Marketed products**
- **Amtagvi (lifileucel):** Its lead product is a one-time, FDA-approved treatment for previously treated advanced melanoma. It is approved in three global markets and administered through more than 100 authorized treatment centers in the U.S., Canada and Australia. More than 1,000 patients have been treated commercially.
- **Proleukin (IL-2):** Sold globally and used as part of the TIL treatment regimen.

**Operating model**
Iovance operates end-to-end, with fully owned, centralized U.S.-based manufacturing at its iCTC facility, scaled to serve thousands of patients annually.

**Pipeline**
- **IOV-LUN-202:** Non-squamous metastatic non-small cell lung cancer, with an sBLA planned in 2027.
- **POSITILITY and OPTILISM:** Biomarker-enriched lung cancer trials.
- **SARATOGA:** Registrational trial in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
- **TILVANCE-301:** Phase 3 trial in frontline advanced melanoma, which also serves as the confirmatory study for Amtagvi.
- **ENDURANCE:** Serous endometrial cancer.
- **Next-generation programs:** IOV-5001 (IL-12 tethered TIL), IOV-4001 (PD-1 inactivated TIL) and IOV-3001 (a modified IL-2 analog).
- **Investigator-sponsored trials:** Studies in renal cell carcinoma, cutaneous squamous cell carcinoma and Merkel cell carcinoma.

**Expansion and intellectual property**
The company is pursuing regulatory approvals in the UK, Switzerland, Brazil and the EU. It holds more than 400 granted or allowed patents, with expected exclusivity through at least 2042. Updated

Latest Activity

IOVAIovance Biotherapeutics
Q3 2026
EPS
-$0.05
est -$0.09+$0.04
Revenue
$121M
est $115M+5.6%

Cash funds operations well into 2029, taking the usual biotech dilution worry off the table for now. Amtagvi demand narrowed the quarterly operating loss to $24.0 million from $94.9 million a year ago, and management reaffirmed full-year product revenue of $410 million to $420 million.

Quarterly EPS — reported vs estimate

IOVA Coverage

Frequently Asked Questions

What does Iovance Biotherapeutics do?

Iovance Biotherapeutics is a commercial-stage biotechnology company that develops, manufactures and delivers polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. **Marketed products** - **Amtagvi (lifileucel):** Its lead product is a one-time, FDA-approved treatment for…

What is the IOVA stock price target?

The Wall Street consensus 12-month price target for IOVA is $14.50. IOVA price prediction →